A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AbbVie
Hackensack Meridian Health
Massachusetts General Hospital
Acerta Pharma BV
Cellectar Biosciences, Inc.
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Seoul National University Hospital
Gilead Sciences
University of Washington
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
BeOne Medicines
BeOne Medicines
University of Ulm
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
French Innovative Leukemia Organisation
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
University of Maryland, Baltimore
City of Hope Medical Center
Fred Hutchinson Cancer Center
Janssen Pharmaceutical K.K.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Ulm
University College, London
BeiGene
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
Mayo Clinic
University of Nebraska
Weill Medical College of Cornell University
Kosin University Gospel Hospital
Agenus Inc.
Shanghai Changzheng Hospital
University of Nebraska
French Innovative Leukemia Organisation
Eastern Cooperative Oncology Group
TG Therapeutics, Inc.
Eastern Cooperative Oncology Group
Abramson Cancer Center at Penn Medicine